Pharvaris N.V.
NASDAQ:PHVSBiotechnology
Healthcare
$31.66 -1.93%
-$0.64 today
- Market cap
- $2.22B
- Beta
- -2.33
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.59
52W Low $16.72High $34.41
Volume 0.28M
Average 0.31M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$137.07M
FY 2025 · Annual
Investing Cash Flow
-$164,619.00
FY 2025 · Annual
Financing Cash Flow
$160.61M
FY 2025 · Annual
+5900.5% YoYCash Flow Statement
EUR
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.66M) | (75.65M) | (99.83M) | (132.4M) | (173.71M) |
| Depreciation & Amortization | 77.37K | 152.94K | 257.55K | 269.56K | 418.35K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.2M | 11.35M | 10.66M | 16.21M | 19.05M |
| Change in Working Capital | 1.58M | 8.38M | (5.86M) | 5.89M | 7.62M |
| Accounts Receivables | (130.5K) | 317.61K | (41.05K) | (34.32K) | (331.34K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 1.71M | 8.06M | (5.82M) | 5.92M | 7.96M |
| Other Non-Cash Items | (11.79M) | (11.39M) | 1.72M | (10.1M) | 9.54M |
| Operating Cash Flow | (44.6M) | (67.16M) | (93.05M) | (120.13M) | (137.07M) |
| Capital Expenditures | (130.03K) | (124.3K) | (89.98K) | (538.09K) | (164.62K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (130.03K) | (124.3K) | (89.98K) | (538.09K) | (164.62K) |
| Debt Repayment | 0 | (119.53K) | (220.51K) | (159.66K) | (219.01K) |
| Common Stock Issued | 156.83M | 9.61M | 342.91M | 2.24M | 171.74M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (13.15M) | (839.97K) | (17.3M) | 592K | (10.91M) |
| Financing Cash Flow | 143.67M | 8.65M | 325.39M | 2.68M | 160.61M |
| Effect of Forex Changes | 11.78M | 11.12M | (2.86M) | 7.49M | (12.42M) |
| Net Change in Cash | 110.72M | (47.52M) | 229.39M | (110.5M) | 10.95M |
| Free Cash Flow | (44.73M) | (67.29M) | (93.14M) | (120.67M) | (137.24M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$173.7M
+ D&A$418.4K
+ Stock-Based Comp$19.1M
+ Deferred Tax$0
+ Working Capital$7.6M
+ Other Non-Cash$9.5M
= Operating Cash Flow-$137.1M
- Capex-$164.6K
= Free Cash Flow-$137.2M
Analysis
FY2025 free cash flow is -$137.2M. FCF conversion is 79.0% of net income. Operating cash flow was -$137.1M, with capex of -$164.6K. The largest bridge item is Stock-Based Comp at $19.1M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 6-K | 6-K filing | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 25, 2026 |
Does PHVS generate free cash flow?
Pharvaris N.V. (PHVS) generated -$137.24M of free cash flow in fiscal 2025.
How much operating cash flow does PHVS produce?
Operating cash flow was -$137.07M, before capital expenditures of $164,619.00.
Continue the stock analysis
Jump to another research area for this company.